Understanding the Recent Shift in Insmed’s Index Inclusion

Insmed (INSM) is drawing fresh attention after being dropped from several Russell value and growth benchmarks in late June, even as investors focus on its recently FDA approved respiratory therapy Brinsupri.

Index removals can influence trading volumes and ownership patterns because many funds track or reference these benchmarks when deciding what to hold. For you, the key question is whether these technical index changes alter the long term appeal of Insmed’s underlying business and pipeline.

Recent trading reflects this tension, with Insmed’s share price up 4.30% over 1 day and 7.95% over 7 days, yet down 31.29% over 90 days. Its very large 3 year total shareholder return highlights how sentiment has swung as investors weigh Brinsupri’s launch, index removals and new leadership appointments.

If Brinsupri’s approval has you thinking about the wider opportunity in respiratory and biotech treatments, it can be helpful to compare Insmed with other healthcare focused AI stocks using the 40 healthcare AI stocks.

With Insmed’s share price recently recovering over the past month but still down sharply over 90 days, and with Brinsupri attracting fresh attention, the key question is simple: is there still value on the table here, or is the market already factoring in future growth?

Most Popular Narrative: 43.4% Undervalued

With Insmed’s last close at $111.60 against a narrative fair value of $197.14, the current gap centers firmly on Brinsupri and its projected earnings power.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Want to see what kind of revenue curve and margin profile could justify that fair value gap? The narrative leans on rapid scaling, rising profitability and a rich future earnings multiple to close the distance.

Result: Fair Value of $197.14 (UNDERVALUED)

However, this hinges on Insmed clearing key hurdles, including potential FDA review delays for Brinsupri and payer pushback that could slow the drug’s uptake and margins.

Another View: Insmed Looks Expensive on Sales-Based Ratios

While the narrative fair value points to upside for Insmed, its current P/S ratio of 29.5x is far above the US Biotechs industry at 12x, the peer average at 8.4x, and the fair ratio of 20x that the market could move towards. That gap suggests meaningful valuation risk if sentiment cools.

For a closer look at how this pricing stacks up against detailed ratio work, check the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Insmed clearly mixed, take a moment to review the underlying data, weigh both sides, and decide where you stand on its risks and rewards by checking the 3 key rewards and 1 important warning sign.

Looking For More Ideas Beyond Insmed?

If Insmed has sharpened your focus on where to put fresh capital to work, do not stop here. Broaden your watchlist with other ideas that fit your style.

• Target potential mispricing by checking out companies flagged in the 44 high quality undervalued stocks.
• Prioritize resilience by scanning stocks in the 74 resilient stocks with low risk scores that score well on downside protection.
• Hunt for future standouts by reviewing the screener containing 18 high quality undiscovered gems before they move onto everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.